Madrigal Pharmaceuticals Corporation is a biopharmaceutical company focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH), also referred to as metabolic dysfunction associated steatohepatitis (MASH). The company has achieved a significant milestone with the accelerated approval of its first therapy, Rezdiffra (resmetirom), by the U.S. Food and Drug Administration (FDA) for treating adults with NASH who have moderate to advanced liver fibrosis. Madrigal is currently conducting a Phase 3 trial for the treatment of NASH with compensated cirrhosis, demonstrating its commitment to addressing critical unmet medical needs in liver disease.